| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514489000 | Ring in alcohol moiety | 34 |
| 20090111872 | STABILIZED PEDIATRIC SUSPENSION OF CARISBAMATE - The present invention provides a stabilized pharmaceutical suspension of carisbamate for pediatric and adult use. More particularly, the suspension is stabilized with hypromellose (HPMC) to prevent crystal growth of the suspended particles and to prevent re-crystallization of the drug product with change in polymorphic form. | 04-30-2009 |
| 20090281179 | CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEUROPATHIC PAIN AND CLUSTER AND MIGRAINE HEADACHE ASSOCIATED PAIN - This invention is directed to a method for preventing or treating neuropathic pain and cluster and migraine headache-associated pain comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) substantially free of other enantiomers or an enantiomeric mixture wherein an enantiomer of Formula (I) predominates: | 11-12-2009 |
| 20090286875 | ISOCYSTENE DERIVATIVES FOR THE TREATMENT OF PAIN - The present invention relates to compounds of formula (I): wherein R | 11-19-2009 |
| 20090312416 | TREATMENT OF SLEEP-WAKE DISORDERS - This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R | 12-17-2009 |
| 20100076075 | METHODS OF TREATING NEUROLOGICAL DISEASE USING ANTAGONISTS OF THE NMDA RECEPTOR COMPLEX - Provided is a method for treating depression with an open-channel antagonists of the NMDA (N-methyl-D-aspartate) receptor complex. The open-channel antagonists include memantine (a 1-amino-3,5-dimethyl-adamantane hydrochloride), felbamate, acamprosate, and MRZ 2/579 (1-amino-1,3,3,5,5-pentamethyl-cyclohexane hydrochloride). The method includes oral, controlled or sustained release, intravenous, rectal, transcutaneous or other preparations such as lipid emulsion or crystal technology administration of the open-channel antagonist. | 03-25-2010 |
| 20120004300 | METHODS FOR TREATING BIPOLAR DISORDER - The invention is directed to a method of treating bipolar disorder in a subject, comprising administering a therapeutically effective amount of a carbamate compound, or pharmaceutically acceptable salt or amide thereof. | 01-05-2012 |
| 20120004301 | METHODS FOR TREATING RESTLESS LEGS SYNDROME - The invention is directed to a method of treating restless legs syndrome in a subject, comprising administering a therapeutically effective amount of a carbamate compound, or pharmaceutically acceptable salt or amide thereof. | 01-05-2012 |
| 20120035258 | METHODS OF USING PRODRUGS OF PREGABALIN - The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders. | 02-09-2012 |
| 20120142769 | METHODS FOR TREATING OR PREVENTING FATIGUE - The present invention relates to the use of compounds of the invention for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments. | 06-07-2012 |
| 20120245226 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER - The invention is directed to a method of treating attention-deficit/hyperactivity disorder (ADHD) in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof. | 09-27-2012 |
| 20120252891 | Vanilloid Fatty Hydroxamates as Therapeutic Anti-inflammatory Pharmaceuticals - Three unique subtypes of N-hydroxyamides and N-hydroxycarbamates containing both the vanilloid moiety (4-hydroxy-3-methoxybenzyl) and a lipophilic aliphatic moiety. Also disclosed are direct syntheses of these vanilloid fatty hydroxamates. The compounds possess inhibitory activity against the enzymes fatty acid amide hydrolase (FAAH) and matrix metallo-proteinase 9 (MMP-9). In addition, these substances bind to the calcium channel protein TRPV1 and inhibit vesicant-induced inflammation in skin and cornea. The compounds have utility in treating topical or systemic inflammatory processes in the skin and/or eye. | 10-04-2012 |
| 20120309826 | STABILIZED PEDIATRIC SUSPENSION OF CARISBAMATE - The present invention provides a stabilized pharmaceutical suspension of carisbamate for pediatric and adult use. More particularly, the suspension is stabilized with hypromellose (HPMC) to prevent crystal growth of the suspended particles and to prevent re-crystallization of the drug product with change in polymorphic form. | 12-06-2012 |
| 20130137764 | Treatment of Sleep-Wake Disorders - This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R | 05-30-2013 |
| 20130165510 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE - The invention relates to inhibitors of trypsin-like serine proteases, including those of the general formula (IV) which, as well as plasmin, also inhibit plasma kallikrein, and to their use as medicaments, preferably for treatment of blood loss, especially in the case of hyperfibrinolytic states, in organ transplants or heart surgery interventions, in particular with a cardiopulmonary bypass, or as a constituent of a fibrin adhesive. | 06-27-2013 |
| 20140275244 | Treatment of Cataplexy - The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. | 09-18-2014 |
| 20140350098 | TREATMENT OF SLEEP-WAKE DISORDERS - This invention is directed to a method of treating Excessive daytime Sleepiness (EDS) in a subject, comprising the step of administering a therapeutically effective amount of a compound of Formula (I): Formula (I) or a pharmaceutically acceptable salt or ester thereof wherein Rx is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms; x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; R1 and R2 can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; R1 and R2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the cyclic compound can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the ox en atom. | 11-27-2014 |
| 20150011625 | METHODS FOR TREATING FIBROMYALGIA SYNDROME - The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof. | 01-08-2015 |
| 20150018414 | Promotion of Smoking Cessation - The present invention relates to a method for promoting cessation or reduction in the smoking and/or chewing of tobacco or nicotine-containing products in a subject in need thereof, comprising administering to the subject an effective amount of certain carbamate compounds. The invention further relates to a method for preventing relapse smoking and/or chewing of tobacco or nicotine-containing products in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. | 01-15-2015 |
| 20150025136 | Treatment for Obesity - The present invention relates to a method for treating or preventing obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. The invention further relates to methods for reducing body weight and/or reducing food intake in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. | 01-22-2015 |
| 20150025137 | METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER - The invention is directed to a method of treating attention-deficit/hyperactivity disorder (ADHD) in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof. | 01-22-2015 |
| 20150306063 | COMPOSITION AND METHOD FOR VAGINAL THERAPY - Provided are a composition and method for vaginal therapy. The composition includes a delivery compound and a pharmaceutically active agent dispersed in the delivery compound. The pharmaceutically active agent includes a centrally acting muscle relaxant. The method for vaginal therapy includes preparing a composition including a pharmaceutically active agent dispersed in a delivery compound, and administering the composition intravaginally. The pharmaceutically active agent includes a muscle relaxant. Another method includes administering the composition extravaginally and then administering the composition intravaginally. | 10-29-2015 |
| 20160008476 | STABILIZED PEDIATRIC SUSPENSION OF CARISBAMATE | 01-14-2016 |
| 20160081970 | TREATMENT FOR OBESITY - The present invention relates to a method for treating or preventing obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. The invention further relates to methods for reducing body weight and/or reducing food intake in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. | 03-24-2016 |
| 20160122291 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and other neuro-inflammatory diseases. | 05-05-2016 |
| 514490000 | Ring attached directly to oxygen of N-C(=0)-0 | 10 |
| 20080214662 | METHODS FOR THE TREATMENT OF DEMENTIA BASED ON APO E GENOTYPE - This invention relates to methods to prevent worsening of and/or to improve cognitive functioning and behaviour problems in patients with dementia by means of ApoE genotyping to guide the use of AChEI drugs, including rivastigimine. Also included are kits for determining ApoE4 status and recommended treatment strategy. | 09-04-2008 |
| 20080255231 | POLYMORPHS OF RIVASTIGMINE HYDROGENTARTRATE - A crystalline rivastigmine hydrogentartrate of Form II and an amorphous rivastigmine hydrogentartrate of Form III. | 10-16-2008 |
| 20090082436 | DEUTERIUM-ENRICHED RIVASTIGMINE - The present application describes deuterium-enriched rivastigmine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
| 20100168229 | Process for the preparation of optically active compounds using transfer hydrogenation - A catalytic process for the preparation of optically active compounds and their conversion thereafter to desired drug substances. In particular, the process relates to the preparation of (S)-3-(1-Dimethylamino-ethyl)-phenol using asymmetric catalytic reduction and transfer hydrogenation, thereby providing an improved route to forming drug substances such as rivastigimine and rivastigimine hydrogen tartrate. | 07-01-2010 |
| 20100227921 | AMINO ACID AND PEPTIDE CARBAMATE PRODRUGS OF TAPENTADOL AND USES THEREOF - Prodrugs of tapentadol with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and a method for providing pain relief with the tapentadol prodrugs are provided herein. Prodrugs having side chains of valine, leucine, isoleucine and glycine amino acids and mono-, di- and tripeptides thereof are preferred. Additionally, methods for avoiding or minimizing the adverse gastrointestinal side effects associated with tapentadol administration, as well as increasing the oral bioavailability of tapentadol are provided herein. | 09-09-2010 |
| 20100240744 | METHODS FOR THE TREATMENT OF DEMENTIA BASED ON APO E GENOTYPE - This invention relates to methods to prevent worsening of and/or to improve cognitive functioning and behavior problems in patients with dementia by means of ApoE genotyping to guide the use of AChEI drugs, including rivastigimine. Also included are kits for determining ApoE4 status and recommended treatment strategy. | 09-23-2010 |
| 20110207813 | PHARMACEUTICAL COMPOSITION WITH GELLING PROPERTIES CONTAINING A TYROSINE DERIVATIVE - The present invention relates to an injectable pharmaceutical composition with gelling properties containing:—an active principle; a hydrophobic and bio-compatible organic liquid; and an organogelling substance, the molecules of which have the capacity to bind together via bonds of low energy, wherein said organogelling substance is chosen among L-tyrosine derivatives responding to the following formula (I) wherein: R1 is an alkyl group containing 1 to 3 carbon atoms, linear or branched; and R2 is a hydrophobic group chosen among aliphatic saturated or unsaturated fatty chains or aryl or arylalkyl groups, Its use as a vector for the release of active principles, as well as its process of preparation. | 08-25-2011 |
| 20120190741 | COMPOUNDS FOR INHIBITION OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE REUPTAKE OR FOR TREATMENT OF DEPRESSION DISORDERS, THEIR PREPARATION PROCESSES AND USES THEREOF - The present invention discloses compounds of formula (I), their optical isomers or pharmaceutically acceptable salts thereof, their preparation and uses thereof, wherein the definitions of R1, R2, R3 and R4 are shown in the description. These compounds are optical isomers or racemic mixtures. After these compounds are uptaken, they are metabolically transformated in vivo into 1-[2-dimethylamino-1-(4-hydroxyphenyl)-ethyl]-cyclohexanol that has neuropharmacological activity, by interrupting reuptake of 5-hydroxytryptamine (5-HT) and/or norepinephrine (NA), which is used for treating diseases associated with central nerve system, such as depression, etc. | 07-26-2012 |
| 20140243407 | ACETAMINOPHEN CONJUGATES, COMPOSITIONS AND METHODS OF USE THEREOF - Acetaminophen conjugates are provided, which have an acetaminophen moiety covalently linked to a second moiety. The conjugates provided may have one or more advantageous properties, including increased water solubility as compared to acetaminophen, reduced toxicity profile as compared to acetaminophen and an altered pharmacokinetic profile. Formulations comprising the conjugates are also provided, as are methods of using the conjugates and kits comprising the conjugates. | 08-28-2014 |
| 20140336253 | COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF RIVASTIGMINE - It has been found that phenyl carbamates, in particular Rivastigmine, can be formulated as a stable TTS by using a monolayer poly alkyl (meth)acrylates, wherein the poly alkyl (meth)acrylates are substantially free of free carboxylate groups. | 11-13-2014 |
